Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 122

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 122
---
3 Plan and the inducement grants described above was 10,325,619, and we had 1,215,876 shares available for future issuance under the 2023 Plan.Stock optionsThe following table presents stock option activity for the three months ended March 31, 2025:Number ofStock OptionsWeighted-AverageExercise PriceOutstanding at December 31, 20245,834,256 $43.48 Granted723,313 33.18 Exercised(1,513)29.64 Cancelled/Forfeited(27,373)58.81 Expired(150,500)107.89 Outstanding at March 31, 20256,378,183 $40.73 Exercisable at March 31, 20254,021,549 $45.85 Vested and expected to vest at March 31, 20256,378,183 $40.73 At March 31, 2025, there was approximately $38.1 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.81 years.Restricted stock unitsThe following table presents RSU activity for the three months ended March 31, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 20241,818,563 $30.31 Granted1,056,231 33.20 Vested(676,891)29.77 Forfeited(26,376)29.82 Unvested shares at March 31, 20252,171,527 $31.89 As of March 31, 2025, there was approximately $61.2 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.30 years.Performance-based stock units The following table presents PSU activity for the three months ended March 31, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 2024374,583 $29.45 Granted185,450 33.12 Unvested shares at March 31, 2025560,033 $30.67 Stock-based compensation expense associated with these PS